Therefore, understanding the precise mechanisms of the PI3K/Akt/mTOR signaling pathway axis and elucidating the underlying PI3K-mediated resistance mechanism can provide a rationale for combination and patient-targeted therapies in CRC. The gene discussed is AKT1; the disease is colorectal carcinoma.